Canopy Growth Corporation has relaunched its Tweed brand in Germany’s medical cannabis market with a new lineup of strains [1].
The move signals the first international product release since Canopy Growth acquired MTL Cannabis Corp., aiming to accelerate the company's growth within the German medical sector [1, 2].
The relaunch features three new strains developed by MTL Cannabis: Pablo’s Revenge, Dante’s Inferno, and Frost’d Flakes [1, 2]. This rollout marks a strategic shift in the company's approach to the European market, leveraging the specific genetics of the MTL partnership to compete in the medical space [1].
Canopy Growth plans to expand this offering further. The company said it intends to introduce up to five additional strains [2]. These new varieties are expected to enter the market in June 2026 [2].
While some reports suggest a different arrangement involving a Portugal-based entity and a strain launched in late 2024, the company's current focus remains on the MTL-developed lineup for this specific German relaunch [1, 2].
The company, based in Smith Falls, Ontario, continues to utilize the Tweed brand as a primary vehicle for its medical cannabis distribution internationally [1].
“The relaunch features three new strains developed by MTL Cannabis: Pablo’s Revenge, Dante’s Inferno, and Frost’d Flakes.”
This relaunch demonstrates Canopy Growth's strategy to integrate acquired assets, specifically MTL Cannabis Corp., into its global supply chain. By targeting the German medical market—one of the largest in Europe—Canopy is attempting to diversify its revenue streams and establish a stronger foothold in a regulatory environment that is increasingly favorable toward medical cannabis.
